Top

Published in:

01-12-2016 | Review Article

Liver metastatic disease: new concepts and biomarker panels to improve individual outcomes

Authors: Olga Golubnitschaja, Krishna Chander Sridhar

Published in: Clinical & Experimental Metastasis | Issue 8/2016

Abstract

Liver cancer, one of the leading causes of all cancer related deaths, belongs to the most malignant cancer types. In fact, the secondary hepatic malignancies (liver metastases) are more common than the primary ones. Almost all solid malignancies can metastasise to the liver. It is well justified that the “treat and wait” approach in the overall management of the liver cancer is not up-to-date and so creation of complex individual patient profiles is needed. This review is specifically focused on the liver metastases originating from the colorectum, breast and prostate cancer. Innovative multilevel diagnostics may procure specific panels of validated biomarkers for predisposition, development and progression of metastatic disease. Creation of the patient specific “molecular portrait” is an essential part of the diagnostic strategy. Contextually, analysis of molecular and cellular patterns in blood samples as the minimally invasive diagnostic tool and construction of diagnostic windows based on individual patient profiling is highly recommended for patient cohorts predisposed to and affected by the liver metastatic disease. Summarised information on risk assessment, predictive and prognostic panels for diagnosis and treatments of the liver metastatic disease in colorectal, breast and prostate cancer is provided.

Chambers AF, Groom AC, MacDonald IC (2002) Metastasis: dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2:563–572. doi:10.1038/nrc865 CrossRefPubMed

Zhang XH-F, Giuliano M, Trivedi MV, Schiff R, Osborne CK (2013) Metastasis dormancy in estrogen receptor-positive breast cancer. Clin Cancer Res 19:6389–6397. doi:10.1158/1078-0432.CCR-13-0838 CrossRefPubMed

Golubnitschaja O, Debald M, Yeghiazaryan K, Kuhn W, Pešta M, Costigliola V, Grech G (2016) Breast cancer epidemic in the early 21st century: evaluation of risk factors, cumulative questionnaires and recommendations for preventive measures. Tumor Biol. doi:10.1007/s13277-016-5168-x

Obenauf AC, Massagué J (2015) Surviving at a distance: organ-specific metastasis. Trends Cancer 1:76–91. doi:10.1016/j.trecan.2015.07.009 CrossRefPubMedPubMedCentral

Ananthakrishnan A, Gogineni V, Saeian K (2006) Epidemiology of primary and secondary liver cancers. Semin Interv Radiol 23:47–63. doi:10.1055/s-2006-939841 CrossRef

Disibio G, French SW (2008) Metastatic patterns of cancers: results from a large autopsy study. Arch Pathol Lab Med 132:931–939. doi:10.1043/1543-2165(2008)132[931:MPOCRF]2.0.CO;2 PubMed

Abraham J-A, Golubnitschaja O (2016) Time for paradigm change in management of hepatocellular carcinoma: is personalised approach in horizon? Pers Med. doi:10.2217/pme-2016-0013

Abraham J-A, Yeghiazaryan K, Golubnitschaja O (2016) Selective internal radiation therapy in treatment of hepatocellular carcinoma: new concepts of personalisation. Pers Med 13(4):347–360. doi:10.2217/pme-2016-0014 CrossRef

K-M Rau H-YK (2005) The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers. Endocr Relat Cancer 12:511–532. doi:10.1677/erc.1.01026 CrossRef

10.

Morgan-Parkes JH (1995) Metastases: mechanisms, pathways, and cascades. Am J Roentgenol 164:1075–1082. doi:10.2214/ajr.164.5.7717206 CrossRef

11.

Sullivan WJ, Christofk HR (2015) The metabolic milieu of metastases. Cell 160:363–364. doi:10.1016/j.cell.2015.01.023 CrossRefPubMed

12.

Miller MC, Doyle GV, Terstappen LWMM, Miller MC, Doyle GV, Terstappen LWMM (2010) Significance of circulating tumor cells detected by the cell search system in patients with metastatic breast colorectal and prostate cancer. J Oncol 2010:e617421. doi:10.1155/2010/617421 CrossRef

13.

Redig AJ, McAllister SS (2013) Breast cancer as a systemic disease: a view of metastasis. J Intern Med 274:113–126. doi:10.1111/joim.12084 CrossRefPubMedPubMedCentral

14.

Elkabets M, Gifford AM, Scheel C, Nilsson B, Reinhardt F, Bray M-A, Carpenter AE, Jirström K, Magnusson K, Ebert BL, Pontén F, Weinberg RA, McAllister SS (2011) Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. J Clin Invest 121:784–799. doi:10.1172/JCI43757 CrossRefPubMedPubMedCentral

15.

Kuznetsov HS, Marsh T, Markens BA, Castaño Z, Greene-Colozzi A, Hay SA, Brown VE, Richardson AL, Signoretti S, Battinelli EM, McAllister SS (2012) Identification of luminal breast cancers that establish a tumor-supportive macroenvironment defined by proangiogenic platelets and bone marrow-derived cells. Cancer Discov 2:1150–1165. doi:10.1158/2159-8290.CD-12-0216 CrossRefPubMedPubMedCentral

16.

McAllister SS, Gifford AM, Greiner AL, Kelleher SP, Saelzler MP, Ince TA, Reinhardt F, Harris LN, Hylander BL, Repasky EA, Weinberg RA (2008) Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 133:994–1005. doi:10.1016/j.cell.2008.04.045 CrossRefPubMedPubMedCentral

17.

Bidard F-C, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Generali D, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Lebofsky R, van Laere SJ, Meier-Stiegen F, Sandri M-T, Vidal-Martinez J, Politaki E, Consoli F, Bottini A, Diaz-Rubio E, Krell J, Dawson S-J, Raimondi C, Rutten A, Janni W, Munzone E, Carañana V, Agelaki S, Almici C, Dirix L, Solomayer E-F, Zorzino L, Johannes H, Reis-Filho JS, Pantel K, Pierga J-Y, Michiels S (2014) Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol 15:406–414. doi:10.1016/S1470-2045(14)70069-5 CrossRefPubMed

18.

Hoon DSB, Kitago M, Kim J, Mori T, Piris A, Szyfelbein K, Mihm MC, Nathanson SD, Padera TP, Chambers AF, Vantyghem SA, MacDonald IC, Shivers SC, Alsarraj M, Reintgen DS, Passlick B, Sienel W, Pantel K (2006) Molecular mechanisms of metastasis. Cancer Metastasis Rev 25:203–220. doi:10.1007/s10555-006-8500-x CrossRefPubMed

19.

Hüsemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, Forni G, Eils R, Fehm T, Riethmüller G, Klein CA (2008) Systemic spread is an early step in breast cancer. Cancer Cell 13:58–68. doi:10.1016/j.ccr.2007.12.003 CrossRefPubMed

20.

Diel IJ, Kaufmann M, Costa SD, Holle R, von Minckwitz G, Solomayer EF, Kaul S, Bastert G (1996) Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 88:1652–1658CrossRefPubMed

21.

Solomayer EF, Diel IJ, Krempien B, Meyberg GC, Gollan C, Krainick U, Wallwiener D, Bastert G (1998) Results of iliac crest biopsies taken from 1465 patients with primary breast cancer. J Cancer Res Clin Oncol 124:44–48CrossRefPubMed

22.

Leary RJ, Sausen M, Kinde I, Papadopoulos N, Carpten JD, Craig D, O’Shaughnessy J, Kinzler KW, Parmigiani G, Vogelstein B, Diaz LA, Velculescu VE (2012) Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med 4:162ra154. doi:10.1126/scitranslmed.3004742 CrossRefPubMedPubMedCentral

23.

Giuliano M, Giordano A, Jackson S, De Giorgi U, Mego M, Cohen EN, Gao H, Anfossi S, Handy BC, Ueno NT, Alvarez RH, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M (2014) Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. Breast Cancer Res 16:440. doi:10.1186/s13058-014-0440-8 CrossRefPubMedPubMedCentral

24.

Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, Tejwani S, Schott AF, O’Rourke MA, Lew DL, Doyle GV, Gralow JR, Livingston RB, Hayes DF (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483–3489. doi:10.1200/JCO.2014.56.2561 CrossRefPubMedPubMedCentral

25.

de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LWWM, Pienta KJ, Raghavan D (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14:6302–6309. doi:10.1158/1078-0432.CCR-08-0872 CrossRefPubMed

26.

Hu B, Rochefort H, Goldkorn A (2013) Circulating tumor cells in prostate cancer. Cancers 5:1676–1690. doi:10.3390/cancers5041676 CrossRefPubMedPubMedCentral

27.

Seeberg LT, Waage A, Brunborg C, Hugenschmidt H, Renolen A, Stav I, Bjørnbeth BA, Brudvik KW, Borgen EF, Naume B, Wiedswang G (2015) Circulating tumor cells in patients with colorectal liver metastasis predict impaired survival. Ann Surg 261:164–171. doi:10.1097/SLA.0000000000000580 CrossRefPubMed

28.

Fleischhacker M, Schmidt B (2015) Extracellular Nucleic Acids and Cancer. In: Circulating nucleic acids in early diagnosis, prognosis and treatment monitoring (Ed: Gahan PB), Book-Series: Advances in predictive, preventive and personalised medicine (Ed.: Golubnitschaja O), Springer, Dordrecht, V.5, ISBN 978-94-017-9167-0

29.

Gupta GP, Minn AJ, Kang Y, Siegel PM, Serganova I, Cordón-Cardo C, Olshen AB, Gerald WL, Massagué J (2005) Identifying site-specific metastasis genes and functions. Cold Spring Harb Symp Quant Biol 70:149–158. doi:10.1101/sqb.2005.70.018 CrossRefPubMed

30.

Denève E, Riethdorf S, Ramos J, Nocca D, Coffy A, Daurès J-P, Maudelonde T, Fabre J-M, Pantel K, Alix-Panabières C (2013) Capture of viable circulating tumor cells in the liver of colorectal cancer patients. Clin Chem 59:1384–1392. doi:10.1373/clinchem.2013.202846 CrossRefPubMed

31.

Singh AD, Bergman L, Seregard S (2005) Uveal melanoma: epidemiologic aspects. Ophthalmol Clin 18:75–84. doi:10.1016/j.ohc.2004.07.002

32.

Costa-Silva B, Aiello NM, Ocean AJ, Singh S, Zhang H, Thakur BK, Becker A, Hoshino A, Mark MT, Molina H, Xiang J, Zhang T, Theilen T-M, García-Santos G, Williams C, Ararso Y, Huang Y, Rodrigues G, Shen T-L, Labori KJ, Lothe IMB, Kure EH, Hernandez J, Doussot A, Ebbesen SH, Grandgenett PM, Hollingsworth MA, Jain M, Mallya K, Batra SK, Jarnagin WR, Schwartz RE, Matei I, Peinado H, Stanger BZ, Bromberg J, Lyden D (2015) Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol 17:816–826. doi:10.1038/ncb3169 CrossRefPubMed

33.

Bao S, Ouyang G, Bai X, Huang Z, Ma C, Liu M, Shao R, Anderson RM, Rich JN, Wang X-F (2004) Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell 5:329–339. doi:10.1016/S1535-6108(04)00081-9 CrossRefPubMed

34.

Loo JM, Scherl A, Nguyen A, Man FY, Weinberg E, Zeng Z, Saltz L, Paty PB, Tavazoie SF (2015) Extracellular metabolic energetics can promote cancer progression. Cell 160:393–406. doi:10.1016/j.cell.2014.12.018 CrossRefPubMedPubMedCentral

35.

Vidal-Vanaclocha F (2011) The Tumor Microenvironment at Different Stages of Hepatic Metastasis. In: Brodt P (ed) Liver Metastasis Biol. Clin. Manag. Springer Netherlands, pp 43–87CrossRef

36.

Takeda A, Stoeltzing O, Ahmad SA, Reinmuth N, Liu W, Parikh A, Fan F, Akagi M, Ellis LM (2002) Role of angiogenesis in the development and growth of liver metastasis. Ann Surg Oncol 9:610–616CrossRefPubMed

37.

Bramhall SR, Gur U, Coldham C, Gunson BK, Mayer AD, McMaster P, Candinas D, Buckels JAC, Mirza DF (2003) Liver resection for colorectal metastases. Ann R Coll Surg Engl 85:334–339. doi:10.1308/003588403769162468 CrossRefPubMedPubMedCentral

38.

Abbas S, Lam V, Hollands M (2011) Ten-year survival after liver resection for colorectal metastases: systematic review and meta-analysis. ISRN Oncol 2011:763245. doi:10.5402/2011/763245 PubMedPubMedCentral

39.

Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, Lillemoe KD, Yeo CJ, Cameron JL (2002) Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235:759–766CrossRefPubMedPubMedCentral

40.

Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–318CrossRefPubMedPubMedCentral

41.

Nordlinger B, Van Cutsem E, Rougier P, Köhne C-H, Ychou M, Sobrero A, Adam R, Arvidsson D, Carrato A, Georgoulias V, Giuliante F, Glimelius B, Golling M, Gruenberger T, Tabernero J, Wasan H, Poston G, European Colorectal Metastases Treatment Group (2007) Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European colorectal metastases treatment group. Eur J Cancer Oxf Engl 1990 43:2037–2045. doi:10.1016/j.ejca.2007.07.017

42.

van Dam RM, Lodewick TM, van den Broek MAJ, de Jong MC, Greve JW, Jansen RLH, Bemelmans MHA, Neumann UP, Olde Damink SWM, Dejong CHC (2014) Outcomes of extended versus limited indications for patients undergoing a liver resection for colorectal cancer liver metastases. HPB 16:550–559. doi:10.1111/hpb.12181 PubMed

43.

Mattar RE, Al-alem F, Simoneau E, Hassanain M (2016) Preoperative selection of patients with colorectal cancer liver metastasis for hepatic resection. World J Gastroenterol 22:567–581. doi:10.3748/wjg.v22.i2.567 CrossRefPubMedPubMedCentral

44.

Nakamura S, Suzuki S, Konno H (1999) Resection of hepatic metastases of colorectal carcinoma: 20 years’ experience. J Hepatobiliary Pancreat Surg 6:16–22CrossRefPubMed

45.

Suzuki S, Sakaguchi T, Yokoi Y, Kurachi K, Okamoto K, Okumura T, Tsuchiya Y, Nakamura T, Konno H, Baba S, Nakamura S (2001) Impact of repeat hepatectomy on recurrent colorectal liver metastases. Surgery 129:421–428. doi:10.1067/msy.2001.112486 CrossRefPubMed

46.

Malafosse R, Penna C, Sa Cunha A, Nordlinger B (2001) Surgical management of hepatic metastases from colorectal malignancies. Ann Oncol Off J Eur Soc Med Oncol ESMO 12:887–894CrossRef

47.

Assumpcao L, Choti MA, Gleisner A et al (2008) Patterns of recurrence following liver resection for colorectal metastases: effect of primary rectal tumor site. Arch Surg 143:743–749. doi:10.1001/archsurg.143.8.743 CrossRefPubMedPubMedCentral

48.

Mullen JT, Ribero D, Reddy SK, Donadon M, Zorzi D, Gautam S, Abdalla EK, Curley SA, Capussotti L, Clary BM, Vauthey J-N (2007) Hepatic insufficiency and mortality in 1059 noncirrhotic patients undergoing major hepatectomy. J Am Coll Surg 204:854–862. doi:10.1016/j.jamcollsurg.2006.12.032 CrossRefPubMed

49.

Abdalla EK, Denys A, Chevalier P, Nemr RA, Vauthey J-N (2004) Total and segmental liver volume variations: implications for liver surgery. Surgery 135:404–410. doi:10.1016/j.surg.2003.08.024 CrossRefPubMed

50.

Abdalla EK, Hicks ME, Vauthey JN (2001) Portal vein embolization: rationale, technique and future prospects. Br J Surg 88:165–175. doi:10.1046/j.1365-2168.2001.01658.x CrossRefPubMed

51.

Vauthey J-N, Pawlik TM, Abdalla EK, Arens JF, Nemr RA, Wei SH, Kennamer DL, Ellis LM, Curley SA (2004) Is extended hepatectomy for hepatobiliary malignancy justified? Ann Surg 239:722–732. doi:10.1097/01.sla.0000124385.83887.d5 CrossRefPubMedPubMedCentral

52.

Behrns KE, Tsiotos GG, DeSouza NF, Krishna MK, Ludwig J, Nagorney DM (1998) Hepatic steatosis as a potential risk factor for major hepatic resection. J Gastrointest Surg Off J Soc Surg Aliment Tract 2:292–298CrossRef

53.

Neal CP, Mann CD, Pointen E, McGregor A, Garcea G, Metcalfe MS, Berry DP, Dennison AR (2012) Influence of hepatic parenchymal histology on outcome following right hepatic trisectionectomy. J Gastrointest Surg Off J Soc Surg Aliment Tract 16:2064–2073. doi:10.1007/s11605-012-2008-1 CrossRef

54.

Reddy SK, Marsh JW, Varley PR, Mock BK, Chopra KB, Geller DA, Tsung A (2012) Underlying steatohepatitis, but not simple hepatic steatosis, increases morbidity after liver resection: a case-control study. Hepatol Baltim Md 56:2221–2230. doi:10.1002/hep.25935 CrossRef

55.

Vauthey J-N, Pawlik TM, Ribero D, Wu T-T, Zorzi D, Hoff PM, Xiong HQ, Eng C, Lauwers GY, Mino-Kenudson M, Risio M, Muratore A, Capussotti L, Curley SA, Abdalla EK (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol Off J Am Soc Clin Oncol 24:2065–2072. doi:10.1200/JCO.2005.05.3074 CrossRef

56.

Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM (2005) Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 200:845–853. doi:10.1016/j.jamcollsurg.2005.01.024 CrossRefPubMed

57.

Zakaria S, Donohue JH, Que FG, Farnell MB, Schleck CD, Ilstrup DM, Nagorney DM (2007) Hepatic resection for colorectal metastases. Ann Surg 246:183–191. doi:10.1097/SLA.0b013e3180603039 CrossRefPubMedPubMedCentral

58.

Leonard GD, Brenner B, Kemeny NE (2005) Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol Off J Am Soc Clin Oncol 23:2038–2048. doi:10.1200/JCO.2005.00.349 CrossRef

59.

Lehmann K, Rickenbacher A, Weber A, Pestalozzi BC, Clavien P-A (2012) Chemotherapy before liver resection of colorectal metastases: friend or foe? Ann Surg 255:237–247. doi:10.1097/SLA.0b013e3182356236 CrossRefPubMed

60.

Pessaux P, Chenard M-P, Bachellier P, Jaeck D (2010) Consequences of chemotherapy on resection of colorectal liver metastases. J Visc Surg 147:e193–e201. doi:10.1016/j.jviscsurg.2010.06.004 CrossRefPubMed

61.

Wang C-C, Li J (2012) An update on chemotherapy of colorectal liver metastases. World J Gastroenterol WJG 18:25–33. doi:10.3748/wjg.v18.i1.25 CrossRefPubMed

62.

Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH (2005) Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a north central cancer treatment group phase II study. J Clin Oncol Off J Am Soc Clin Oncol 23:9243–9249. doi:10.1200/JCO.2005.07.740 CrossRef

63.

Bismuth H, Adam R, Lévi F, Farabos C, Waechter F, Castaing D, Majno P, Engerran L (1996) Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224:509–522CrossRefPubMedPubMedCentral

64.

Khatri VP, Chee KG, Petrelli NJ (2007) Modern multimodality approach to hepatic colorectal metastases: solutions and controversies. Surg Oncol 16:71–83. doi:10.1016/j.suronc.2007.05.001 CrossRefPubMed

65.

Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, Giacchetti S, Paule B, Kunstlinger F, Ghémard O, Levi F, Bismuth H (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy. Ann Surg 240:644–658. doi:10.1097/01.sla.0000141198.92114.f6 CrossRefPubMedPubMedCentral

66.

Golubnitschaja O, Cebioglu M, Yeghiazaryan K, Pieper CC, Schild HH (2014) “Molecular signature” in blood of liver cancer diagnosed patients as a criterion for optimal therapy modalities. EPMA J 5:A38. doi:10.1186/1878-5085-5-S1-A38 CrossRefPubMedCentral

67.

De Rosa M, Pace U, Rega D, Costabile V, Duraturo F, Izzo P, Delrio P (2015) Genetics, diagnosis and management of colorectal cancer (review). Oncol Rep 34:1087–1096. doi:10.3892/or.2015.4108 PubMed

68.

Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier A-M (2006) Epidemiology and Management of Liver Metastases From Colorectal Cancer. Ann Surg 244:254–259. doi:10.1097/01.sla.0000217629.94941.cf CrossRef

69.

Risbridger GP, Davis ID, Birrell SN, Tilley WD (2010) Breast and prostate cancer: more similar than different. Nat Rev Cancer 10:205–212. doi:10.1038/nrc2795 CrossRefPubMed

70.

Auguste P, Fallavollita L, Wang N, Burnier J, Bikfalvi A, Brodt P (2007) The host inflammatory response promotes liver metastasis by increasing tumor cell arrest and extravasation. Am J Pathol 170:1781–1792. doi:10.2353/ajpath.2007.060886 CrossRefPubMedPubMedCentral

71.

Khatib A-M, Auguste P, Fallavollita L, Wang N, Samani A, Kontogiannea M, Meterissian S, Brodt P (2005) Characterization of the host proinflammatory response to tumor cells during the initial stages of liver metastasis. Am J Pathol 167:749–759. doi:10.1016/S0002-9440(10)62048-2 CrossRefPubMedPubMedCentral

72.

Gout S, Huot J (2008) Role of cancer microenvironment in metastasis: focus on colon cancer. Cancer Microenviron 1:69–83. doi:10.1007/s12307-008-0007-2 CrossRefPubMedPubMedCentral

73.

Yim K-L (2011) Microsatellite instability in metastatic colorectal cancer: a review of pathology, response to chemotherapy and clinical outcome. Med Oncol 29:1796–1801. doi:10.1007/s12032-011-0050-6 CrossRefPubMed

74.

Zong Z, Zhou T, Rao L, Jiang Z, Li Y, Hou Z, Yang B, Han F, Chen S (2016) Musashi2 as a novel predictive biomarker for liver metastasis and poor prognosis in colorectal cancer. Cancer Med. doi:10.1002/cam4.624 PubMedPubMedCentral

75.

Ito T, Kwon HY, Zimdahl B, Congdon KL, Blum J, Lento WE, Zhao C, Lagoo A, Gerrard G, Foroni L, Goldman J, Goh H, Kim S-H, Kim D-W, Chuah C, Oehler VG, Radich JP, Jordan CT, Reya T (2010) Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature 466:765–768. doi:10.1038/nature09171 CrossRefPubMedPubMedCentral

76.

Watanabe M, Ohnishi Y, Inoue H, Wato M, Tanaka A, Kakudo K, Nozaki M (2014) NANOG expression correlates with differentiation, metastasis and resistance to preoperative adjuvant therapy in oral squamous cell carcinoma. Oncol Lett 7:35–40. doi:10.3892/ol.2013.1690 PubMed

77.

Xu F, Dai C, Zhang R, Zhao Y, Peng S, Jia C (2012) Nanog: A Potential Biomarker for Liver Metastasis of Colorectal Cancer. Dig Dis Sci 57:2340–2346. doi:10.1007/s10620-012-2182-8 CrossRefPubMed

78.

Bröker MEE, Lalmahomed ZS, Roest HP, van Huizen NA, Dekker LJM, Calame W, Verhoef C, IJzermans JNM, Luider TM (2013) Collagen peptides in urine: a new promising biomarker for the detection of colorectal liver metastases. PLoS One 8:e70918. doi:10.1371/journal.pone.0070918 CrossRefPubMedPubMedCentral

79.

Colussi D, Brandi G, Bazzoli F, Ricciardiello L (2013) Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci 14:16365–16385. doi:10.3390/ijms140816365 CrossRefPubMedPubMedCentral

80.

Karnes WE, Shattuck-Brandt R, Burgart LJ, DuBois RN, Tester DJ, Cunningham JM, Kim CY, McDonnell SK, Schaid DJ, Thibodeau SN (1998) Reduced COX-2 protein in colorectal cancer with defective mismatch repair. Cancer Res 58:5473–5477PubMed

81.

Ogino S, Brahmandam M, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS (2006) Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG Island methylator phenotype in colorectal cancer. Neoplasia 8:458–464CrossRefPubMedPubMedCentral

82.

Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, Brabletz T (2008) A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 9:582–589. doi:10.1038/embor.2008.74 CrossRefPubMedPubMedCentral

83.

Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D, zur Hausen A, Brunton VG, Morton J, Sansom O, Schüler J, Stemmler MP, Herzberger C, Hopt U, Keck T, Brabletz S, Brabletz T (2009) The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 11:1487–1495. doi:10.1038/ncb1998 CrossRefPubMed

84.

Toiyama Y, Hur K, Tanaka K, Inoue Y, Kusunoki M, Boland CR, Goel A (2014) Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Ann Surg 259:735–743. doi:10.1097/SLA.0b013e3182a6909d CrossRefPubMedPubMedCentral

85.

Hur K, Toiyama Y, Takahashi M, Balaguer F, Nagasaka T, Koike J, Hemmi H, Koi M, Boland CR, Goel A (2013) MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut 62:1315–1326. doi:10.1136/gutjnl-2011-301846 CrossRefPubMed

86.

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108. doi:10.3322/caac.21262 CrossRefPubMed

87.

Ekwueme DU, Guy GP, Rim SH, White A, Hall IJ, Fairley TL, Dean HD (2014) Health and economic impact of breast cancer mortality in young women, 1970–2008. Am J Prev Med 46:71–79. doi:10.1016/j.amepre.2013.08.016 CrossRefPubMed

88.

Golubnitschaja O, Yeghiazaryan K, Stricker H, Trog D, Schild HH, Berliner L (2016) Patients with hepatic breast cancer metastases demonstrate highly specific profiles of matrix metalloproteinases MMP-2 and MMP-9 after SIRT treatment as compared to other primary and secondary liver tumours. BMC Cancer 16(1):357. doi:10.1186/s12885-016-2382-2 CrossRefPubMedPubMedCentral

89.

Tampellini M, Berruti A, Gerbino A, Buniva T, Torta M, Gorzegno G, Faggiuolo R, Cannone R, Farris A, Destefanis M, Moro G, Deltetto F, Dogliotti L (1997) Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease. Br J Cancer 75:698–702CrossRefPubMedPubMedCentral

90.

Makki J (2015) Diversity of breast carcinoma: histological subtypes and clinical relevance. Clin Med Insights Pathol 8:23–31. doi:10.4137/CPath.S31563 CrossRefPubMedPubMedCentral

91.

Weigelt B, Peterse JL, van’t Veer LJ (2005) Breast cancer metastasis: markers and models. Nat Rev Cancer 5:591–602. doi:10.1038/nrc1670 CrossRefPubMed

92.

Osman MA, Hennessy BT (2015) Obesity correlation with metastases development and response to first-line metastatic chemotherapy in breast cancer. Clin Med Insights Oncol 9:105–112. doi:10.4137/CMO.S32812 CrossRefPubMedPubMedCentral

93.

Chan DSM, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A, Navarro Rosenblatt D, Thune I, Vieira R, Norat T (2014) Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol Off J Eur Soc Med Oncol ESMO 25:1901–1914. doi:10.1093/annonc/mdu042 CrossRef

94.

Weinrich M, Weiß Christel, Schuld J, Rau BM (2014) Liver resections of isolated liver metastasis in breast cancer: results and possible prognostic factors. HPB Surg 2014:e893829. doi:10.1155/2014/893829 CrossRef

95.

Girotra S, Yeghiazaryan K, Golubnitschaja O (2016) Potential biomarker panels in overall breast cancer management: advancements by multi-level diagnostics. Pers Med. doi:10.2217/pme-2016-0020

96.

Golubnitschaja O, Yeghiazaryan K, Costigliola V, Trog D, Braun M, Debald M, Kuhn W, Schild HH (2013) Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon? EPMA J 4:6. doi:10.1186/1878-5085-4-6 CrossRefPubMedPubMedCentral

97.

Debald M, Yeghiazaryan K, Cebioglu M, Kuhn W, Schild HH, Golubnitschaja O (2013) “Suspect molecular signature” in blood as the indicator of undiagnosed breast cancer, cancer risk and targeted prevention. EPMA J 4:22. doi:10.1186/1878-5085-4-22 CrossRefPubMedPubMedCentral

98.

Kimbung S, Kovács A, Bendahl P-O, Malmström P, Fernö M, Hatschek T, Hedenfalk I (2014) Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences. Mol Oncol 8:119–128. doi:10.1016/j.molonc.2013.10.002 CrossRefPubMed

99.

Clevers H, Loh KM, Nusse R (2014) Stem cell signaling. An integral program for tissue renewal and regeneration: wnt signaling and stem cell control. Science 346:1248012. doi:10.1126/science.1248012 CrossRefPubMed

100.

Nusse R (2012) Wnt signaling. Cold Spring Harb Perspect Biol. doi:10.1101/cshperspect.a011163

101.

Reya T, Clevers H (2005) Wnt signalling in stem cells and cancer. Nature 434:843–850. doi:10.1038/nature03319 CrossRefPubMed

102.

Henry C, Quadir A, Hawkins NJ, Jary E, Llamosas E, Kumar D, Daniels B, Ward RL, Ford CE (2015) Expression of the novel Wnt receptor ROR2 is increased in breast cancer and may regulate both β-catenin dependent and independent Wnt signalling. J Cancer Res Clin Oncol 141:243–254. doi:10.1007/s00432-014-1824-y CrossRefPubMed

103.

Zhang S, Chen L, Cui B, Chuang H-Y, Yu J, Wang-Rodriguez J, Tang L, Chen G, Basak GW, Kipps TJ (2012) ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PLoS One 7:e31127. doi:10.1371/journal.pone.0031127 CrossRefPubMedPubMedCentral

104.

Bleckmann A, Conradi L-C, Menck K, Schmick NA, Schubert A, Rietkötter E, Arackal J, Middel P, Schambony A, Liersch T, Homayounfar K, Beißbarth T, Klemm F, Binder C, Pukrop T (2016) β-catenin-independent WNT signaling and Ki67 in contrast to the estrogen receptor status are prognostic and associated with poor prognosis in breast cancer liver metastases. Clin Exp Metastasis. doi:10.1007/s10585-016-9780-3 PubMedPubMedCentral

105.

Bubendorf L, Schöpfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ (2000) Metastatic patterns of prostate cancer: an autopsy study of 1589 patients. Hum Pathol 31:578–583CrossRefPubMed

106.

Pouessel D, Gallet B, Bibeau F, Avancès C, Iborra F, Sénesse P, Culine S (2007) Liver metastases in prostate carcinoma: clinical characteristics and outcome. BJU Int 99:807–811. doi:10.1111/j.1464-410X.2006.06663.x CrossRefPubMed

107.

Treatment for advanced prostate cancer. http://www.uptodate.com/contents/treatment-for-advanced-prostate-cancer-beyond-the-basics. Accessed 18 Mar 2016

108.

Fowler JE, Sanders J, Bigler SA, Rigdon J, Kilambi NK, Land SA (2000) Percent free prostate specific antigen and cancer detection in black and white men with total prostate specific antigen 2.5–9.9 ng./ml. J Urol 163:1467–1470CrossRefPubMed

109.

Moul JW, Douglas TH, McCarthy WF, McLeod DG (1996) Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. J Urol 155:1667–1673CrossRefPubMed

110.

Drake CG (2014) Visceral metastases and prostate cancer treatment: “die hard”, “tough neighborhoods”, or “evil humors”? Oncol (Williston Park NY) 28:974–980

111.

Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM (2006) Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 24:677–688. doi:10.1016/j.immuni.2006.06.002 CrossRefPubMed

112.

Azevedo A, Cunha V, Teixeira AL, Medeiros R (2011) IL-6/IL-6R as a potential key signaling pathway in prostate cancer development. World J Clin Oncol 2:384–396. doi:10.5306/wjco.v2.i12.384 CrossRefPubMedPubMedCentral

113.

Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444. doi:10.1038/nature07205 CrossRefPubMed

114.

Yoshimura T, Matsushima K, Tanaka S, Robinson EA, Appella E, Oppenheim JJ, Leonard EJ (1987) Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc Natl Acad Sci USA 84:9233–9237CrossRefPubMedPubMedCentral

115.

Huang S, Mills L, Mian B, Tellez C, McCarty M, Yang X-D, Gudas JM, Bar-Eli M (2002) Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol 161:125–134CrossRefPubMedPubMedCentral

116.

Goodman OB, Flaig TW, Molina A, Mulders PFA, Fizazi K, Suttmann H, Li J, Kheoh T, de Bono JS, Scher HI (2014) Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 17:34–39. doi:10.1038/pcan.2013.41 CrossRefPubMed

117.

Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B, MacVicar G, Raghavan D (2006) Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest oncology group trial 9346 (INT-0162). J Clin Oncol 24:3984–3990. doi:10.1200/JCO.2006.06.4246 CrossRefPubMed

118.

Renee C, Prins BLR (2010) C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results. Urol Oncol 30:33–37. doi:10.1016/j.urolonc.2009.11.012

119.

Cox TR, Rumney RMH, Schoof EM, Perryman L, Høye AM, Agrawal A, Bird D, Latif NA, Forrest H, Evans HR, Huggins ID, Lang G, Linding R, Gartland A, Erler JT (2015) The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature 522(7554):106–110. doi:10.1038/nature14492 CrossRefPubMedPubMedCentral

120.

Golubnitschaja O, Debald M, Kuhn W, Yeghiazaryan K, Bubnov RV, Goncharenko VM, Lushchyk U, Grech G, Konieczka K (2016) Flammer syndrome and potential formation of pre-metastatic niches: a multi-centred study on phenotyping, patient stratification, prediction and potential prevention of aggressive breast cancer and metastatic disease. EPMA J 7(Suppl 1):A25

Title: Liver metastatic disease: new concepts and biomarker panels to improve individual outcomes
Authors: Olga Golubnitschaja
Krishna Chander Sridhar
Publication date: 01-12-2016
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 8/2016
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-016-9816-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2016

Impact of primary para-aortic lymphadenectomy on distant failure in locally advanced cervical cancer patients treated in the era of image-guided adaptive brachytherapy

Ectopic expression of MCAM/MUC18 increases in vitro motility and invasiveness, but decreases in vivo tumorigenesis and metastasis of a mouse melanoma K1735-9 subline in a syngeneic mouse model

A journey beyond apoptosis: new enigma of controlling metastasis by pro-apoptotic Par-4

Prognostic value of 5-microRNA based signature in T2-T3N0 colon cancer

CD4+FOXP3+ T regulatory cells decrease and CD3+CD8+ T cells recruitment in TILs from melanoma metastases after electrochemotherapy

Impact of disease free status on prognosis in metastatic non-small round cell soft tissue sarcomas

Keynote webinar | Spotlight on antibody–drug conjugates in cancer